Abatacept in B7-1-positive proteinuric kidney disease

Chih Chuan Yu; Alessia Fornoni; Astrid Weins; Samy Hakroush; Dony Maiguel; Junichiro Sageshima; Linda Chen; Gaetano Ciancio; Mohd Hafeez Faridi; Daniel Behr; Kirk N. Campbell; Jer Ming Chang; Hung Chun Chen; Jun Oh; Christian Faul; M. Amin Arnaout; Paolo Fiorina; Vineet Gupta; Anna Greka; George W. Burke; Peter Mundel

doi:10.1056/NEJMoa1304572

Abatacept in B7-1-positive proteinuric kidney disease

Chih Chuan Yu
, Alessia Fornoni
, Astrid Weins
, Samy Hakroush
, Dony Maiguel
, Junichiro Sageshima
, Linda Chen
, Gaetano Ciancio
, Mohd Hafeez Faridi
, Daniel Behr
, Kirk N. Campbell
, Jer Ming Chang
, Hung Chun Chen
, Jun Oh
, Christian Faul
, M. Amin Arnaout
, Paolo Fiorina
, Vineet Gupta
, Anna Greka
, George W. Burke

Peter Mundel

Research output: Contribution to journal › Article › peer-review

346 Scopus citations

Abstract

Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.

Original language	English (US)
Pages (from-to)	2416-2423
Number of pages	8
Journal	New England Journal of Medicine
Volume	369
Issue number	25
DOIs	https://doi.org/10.1056/NEJMoa1304572
State	Published - 2013
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMoa1304572

Cite this

Yu, C. C., Fornoni, A., Weins, A., Hakroush, S., Maiguel, D., Sageshima, J., Chen, L., Ciancio, G., Faridi, M. H., Behr, D., Campbell, K. N., Chang, J. M., Chen, H. C., Oh, J., Faul, C., Amin Arnaout, M., Fiorina, P., Gupta, V., Greka, A., ... Mundel, P. (2013). Abatacept in B7-1-positive proteinuric kidney disease. New England Journal of Medicine, 369(25), 2416-2423. https://doi.org/10.1056/NEJMoa1304572

Yu, CC, Fornoni, A, Weins, A, Hakroush, S, Maiguel, D, Sageshima, J, Chen, L, Ciancio, G, Faridi, MH, Behr, D, Campbell, KN, Chang, JM, Chen, HC, Oh, J, Faul, C, Amin Arnaout, M, Fiorina, P, Gupta, V, Greka, A, Burke, GW & Mundel, P 2013, 'Abatacept in B7-1-positive proteinuric kidney disease', New England Journal of Medicine, vol. 369, no. 25, pp. 2416-2423. https://doi.org/10.1056/NEJMoa1304572

@article{28cc4b755a784d38b4a2833c65d58ba1,

title = "Abatacept in B7-1-positive proteinuric kidney disease",

abstract = "Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.",

author = "Yu, \{Chih Chuan\} and Alessia Fornoni and Astrid Weins and Samy Hakroush and Dony Maiguel and Junichiro Sageshima and Linda Chen and Gaetano Ciancio and Faridi, \{Mohd Hafeez\} and Daniel Behr and Campbell, \{Kirk N.\} and Chang, \{Jer Ming\} and Chen, \{Hung Chun\} and Jun Oh and Christian Faul and \{Amin Arnaout\}, M. and Paolo Fiorina and Vineet Gupta and Anna Greka and Burke, \{George W.\} and Peter Mundel",

year = "2013",

doi = "10.1056/NEJMoa1304572",

language = "English (US)",

volume = "369",

pages = "2416--2423",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "25",

}

TY - JOUR

T1 - Abatacept in B7-1-positive proteinuric kidney disease

AU - Yu, Chih Chuan

AU - Fornoni, Alessia

AU - Weins, Astrid

AU - Hakroush, Samy

AU - Maiguel, Dony

AU - Sageshima, Junichiro

AU - Chen, Linda

AU - Ciancio, Gaetano

AU - Faridi, Mohd Hafeez

AU - Behr, Daniel

AU - Campbell, Kirk N.

AU - Chang, Jer Ming

AU - Chen, Hung Chun

AU - Oh, Jun

AU - Faul, Christian

AU - Amin Arnaout, M.

AU - Fiorina, Paolo

AU - Gupta, Vineet

AU - Greka, Anna

AU - Burke, George W.

AU - Mundel, Peter

PY - 2013

Y1 - 2013

N2 - Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.

AB - Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.

UR - https://www.scopus.com/pages/publications/84890409760

UR - https://www.scopus.com/pages/publications/84890409760#tab=citedBy

U2 - 10.1056/NEJMoa1304572

DO - 10.1056/NEJMoa1304572

M3 - Article

AN - SCOPUS:84890409760

SN - 0028-4793

VL - 369

SP - 2416

EP - 2423

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 25

ER -

Abatacept in B7-1-positive proteinuric kidney disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this